ArticleCureus2026
The First Moroccan Experience of Personalized Template‑Guided High-Dose-Rate Brachytherapy for Organ Preservation in Glans Squamous Cell Carcinoma: Game Changer or Challenge?
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Squamous cell carcinoma of the glans is a rare malignancy, often diagnosed at an advanced stage, and its management remains challenging. Therapeutic approaches are multimodal and depend on tumor stage, risk of recurrence, nodal involvement, and disease extent. Organ-preserving strategies are increasingly advocated, particularly in patients who refuse mutilating surgery. We report the first Moroccan case of a 50-year-old man diagnosed with a T2N0M0 glans carcinoma, treated with high-dose-rate (HDR) brachytherapy using a customized template following refusal of partial penectomy. Initial treatment achieved adequate tumor coverage without acute toxicity, with no evidence of necrosis or skin ulceration. A superficial recurrence in the previously irradiated area was detected four months later and was successfully treated with salvage HDR brachytherapy. At 18 months of follow-up, urinary function was preserved and partial sexual function maintained, with no severe complications. This case illustrates that personalized HDR brachytherapy may represent a feasible, safe, and organ-preserving alternative in patients refusing mutilating surgery, supporting its applicability even in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.